FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912328078> ?p ?o ?g. }

• W2912328078 endingPage "836" @default.
• W2912328078 startingPage "827" @default.
• W2912328078 abstract "Rationale & ObjectiveA large residual risk for atherosclerotic cardiovascular disease (ASCVD) remains in the setting of chronic kidney disease (CKD) despite treatment with statins. We sought to evaluate the associations of lipid and apolipoprotein levels with risk for ASCVD in individuals with CKD.Study DesignProspective cohort study.Settings & ParticipantsAdults aged 21 to 74 years with non–dialysis-dependent CKD at baseline enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study in 7 clinical study centers in the United States.PredictorBaseline total cholesterol, non–high-density lipoprotein cholesterol (non–HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo-B), HDL-C, and apolipoprotein AI (Apo-AI) values stratified into tertiles.OutcomeA composite ASCVD event of myocardial infarction or ischemic stroke.Analytic ApproachMultivariable Cox proportional hazards regression to estimate the risk for ASCVD for each tertile of lipoprotein predictor.ResultsAmong 3,811 CRIC participants (mean age, 57.7 years; 41.8% white), there were 451 ASCVD events during a median follow-up of 7.9 years. There was increased ASCVD risk among participants with VLDL-C levels in the highest tertile (HR, 1.28; 95% CI, 1.01-1.64), Apo-B levels in the middle tertile (HR, 1.30; 95% CI, 1.03-1.64), HDL-C levels in the middle and lowest tertiles (HRs of 1.40 [95% CI, 1.08-1.83] and 1.77 [95% CI, 1.35-2.33], respectively), and Apo-AI levels in the middle and lowest tertiles (HRs of 1.77 [95% CI, 1.02-1.74] and 1.77 [95% CI, 1.36-2.32], respectively). LDL-C level was not significantly associated with the ASCVD outcome in this population (HR, 1.00 [95% CI, 0.77-1.30] for the highest tertile).LimitationsAssociations based on observational data do not permit inferences about causal associations.ConclusionsHigher VLDL-C and Apo-B levels, as well as lower HDL-C and Apo-AI levels, are associated with increased risk for ASCVD. These findings support future investigations into pharmacologic targeting of lipoproteins beyond LDL-C, such as triglyceride-rich lipoproteins, to reduce residual risk for ASCVD among individuals with CKD. A large residual risk for atherosclerotic cardiovascular disease (ASCVD) remains in the setting of chronic kidney disease (CKD) despite treatment with statins. We sought to evaluate the associations of lipid and apolipoprotein levels with risk for ASCVD in individuals with CKD. Prospective cohort study. Adults aged 21 to 74 years with non–dialysis-dependent CKD at baseline enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study in 7 clinical study centers in the United States. Baseline total cholesterol, non–high-density lipoprotein cholesterol (non–HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo-B), HDL-C, and apolipoprotein AI (Apo-AI) values stratified into tertiles. A composite ASCVD event of myocardial infarction or ischemic stroke. Multivariable Cox proportional hazards regression to estimate the risk for ASCVD for each tertile of lipoprotein predictor. Among 3,811 CRIC participants (mean age, 57.7 years; 41.8% white), there were 451 ASCVD events during a median follow-up of 7.9 years. There was increased ASCVD risk among participants with VLDL-C levels in the highest tertile (HR, 1.28; 95% CI, 1.01-1.64), Apo-B levels in the middle tertile (HR, 1.30; 95% CI, 1.03-1.64), HDL-C levels in the middle and lowest tertiles (HRs of 1.40 [95% CI, 1.08-1.83] and 1.77 [95% CI, 1.35-2.33], respectively), and Apo-AI levels in the middle and lowest tertiles (HRs of 1.77 [95% CI, 1.02-1.74] and 1.77 [95% CI, 1.36-2.32], respectively). LDL-C level was not significantly associated with the ASCVD outcome in this population (HR, 1.00 [95% CI, 0.77-1.30] for the highest tertile). Associations based on observational data do not permit inferences about causal associations. Higher VLDL-C and Apo-B levels, as well as lower HDL-C and Apo-AI levels, are associated with increased risk for ASCVD. These findings support future investigations into pharmacologic targeting of lipoproteins beyond LDL-C, such as triglyceride-rich lipoproteins, to reduce residual risk for ASCVD among individuals with CKD." @default.
• W2912328078 created "2019-02-21" @default.
• W2912328078 creator A5015656712 @default.
• W2912328078 creator A5016894949 @default.
• W2912328078 creator A5022841543 @default.
• W2912328078 creator A5026846209 @default.
• W2912328078 creator A5033996338 @default.
• W2912328078 creator A5040913447 @default.
• W2912328078 creator A5047317486 @default.
• W2912328078 creator A5048379858 @default.
• W2912328078 creator A5048680434 @default.
• W2912328078 creator A5055512614 @default.
• W2912328078 creator A5058217417 @default.
• W2912328078 creator A5059631475 @default.
• W2912328078 creator A5065023946 @default.
• W2912328078 creator A5065755363 @default.
• W2912328078 creator A5067149045 @default.
• W2912328078 creator A5069526163 @default.
• W2912328078 creator A5073110767 @default.
• W2912328078 creator A5080156777 @default.
• W2912328078 creator A5085929316 @default.
• W2912328078 creator A5090601106 @default.
• W2912328078 date "2019-06-01" @default.
• W2912328078 modified "2023-10-17" @default.
• W2912328078 title "Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD" @default.
• W2912328078 cites W1273733467 @default.
• W2912328078 cites W138661497 @default.
• W2912328078 cites W1826064705 @default.
• W2912328078 cites W1902555847 @default.
• W2912328078 cites W1972458772 @default.
• W2912328078 cites W1978239396 @default.
• W2912328078 cites W1993577107 @default.
• W2912328078 cites W2042206096 @default.
• W2912328078 cites W2048760408 @default.
• W2912328078 cites W2049984827 @default.
• W2912328078 cites W2056503496 @default.
• W2912328078 cites W2066523471 @default.
• W2912328078 cites W2068944125 @default.
• W2912328078 cites W2074091766 @default.
• W2912328078 cites W2081604608 @default.
• W2912328078 cites W2101333957 @default.
• W2912328078 cites W2108790161 @default.
• W2912328078 cites W2112481616 @default.
• W2912328078 cites W2118825330 @default.
• W2912328078 cites W2124481954 @default.
• W2912328078 cites W2126634142 @default.
• W2912328078 cites W2134120087 @default.
• W2912328078 cites W2134777998 @default.
• W2912328078 cites W2145632027 @default.
• W2912328078 cites W2146278956 @default.
• W2912328078 cites W2148983669 @default.
• W2912328078 cites W2151052098 @default.
• W2912328078 cites W2160134719 @default.
• W2912328078 cites W2168700908 @default.
• W2912328078 cites W2286999219 @default.
• W2912328078 cites W2296190881 @default.
• W2912328078 cites W2344530571 @default.
• W2912328078 cites W2414191002 @default.
• W2912328078 cites W2443007458 @default.
• W2912328078 cites W2475261460 @default.
• W2912328078 cites W2512895854 @default.
• W2912328078 cites W2530844910 @default.
• W2912328078 cites W2551232524 @default.
• W2912328078 cites W2560327818 @default.
• W2912328078 cites W2565823552 @default.
• W2912328078 cites W2586813559 @default.
• W2912328078 cites W2588878434 @default.
• W2912328078 cites W2614096895 @default.
• W2912328078 cites W2616536890 @default.
• W2912328078 cites W2759870717 @default.
• W2912328078 cites W2770674556 @default.
• W2912328078 cites W2788166026 @default.
• W2912328078 cites W2915967003 @default.
• W2912328078 cites W4252905168 @default.
• W2912328078 cites W4293084779 @default.
• W2912328078 doi "https://doi.org/10.1053/j.ajkd.2018.11.010" @default.
• W2912328078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6615056" @default.
• W2912328078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30686529" @default.
• W2912328078 hasPublicationYear "2019" @default.
• W2912328078 type Work @default.
• W2912328078 sameAs 2912328078 @default.
• W2912328078 citedByCount "39" @default.
• W2912328078 countsByYear W29123280782019 @default.
• W2912328078 countsByYear W29123280782020 @default.
• W2912328078 countsByYear W29123280782021 @default.
• W2912328078 countsByYear W29123280782022 @default.
• W2912328078 countsByYear W29123280782023 @default.
• W2912328078 crossrefType "journal-article" @default.
• W2912328078 hasAuthorship W2912328078A5015656712 @default.
• W2912328078 hasAuthorship W2912328078A5016894949 @default.
• W2912328078 hasAuthorship W2912328078A5022841543 @default.
• W2912328078 hasAuthorship W2912328078A5026846209 @default.
• W2912328078 hasAuthorship W2912328078A5033996338 @default.
• W2912328078 hasAuthorship W2912328078A5040913447 @default.
• W2912328078 hasAuthorship W2912328078A5047317486 @default.
• W2912328078 hasAuthorship W2912328078A5048379858 @default.
• W2912328078 hasAuthorship W2912328078A5048680434 @default.
• W2912328078 hasAuthorship W2912328078A5055512614 @default.

• next